This is a preview of subscription content, log in via an institution to check access.
Reference
Aspinall SL, et al. Incremental Cost Effectiveness of Pharmacist-Managed Erythropoiesis-Stimulating Agent Clinics for Non-Dialysis-Dependent Chronic Kidney Disease Patients. Applied Health Economics and Health Policy : 5 Oct 2013. Available from: URL: http://dx.doi.org/10.1007/s40258-013-0057-6
Rights and permissions
About this article
Cite this article
Pharmacist-managed ESA dosing dominates in NDD-CKD. PharmacoEcon Outcomes News 689, 9 (2013). https://doi.org/10.1007/s40274-013-0801-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0801-z